Aptose signs up to $8.5M uncommitted loan from Hanmi for Tuspetinib AML clinical development

Aptose Biosciences Inc.

Loan agreement with Hanmi Pharmaceutical for up to $8.5M uncommitted non-revolving facility.
Funds to be used for Tuspetinib triple drug therapy for newly diagnosed AML, accounts payable, and TUS-related corporate purposes.
Advances up to $2.5M each, available until Dec 31, 2025; maturity date Aug 31, 2028.
Loan bears 6% interest per annum; secured by first ranking security on all personal property of Aptose and subsidiary guarantees.
Previous 2024 facility agreement also exists; new loan is separate.

item 1.01item 2.03item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.